Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, announced on Monday its financial results for the fiscal year ended 31 March 2025.
Revenue totalled USD119.97m, down from USD123.99m in the same period of last year.
Gross profit was USD3.84m, compared to USD4.88m a year earlier, while gross margin was 3.2% compared to 3.9% in the year to 31 March 2024.
Ridgetech reported net income of USD10.20m, or USD1.84 per basic and diluted earnings per share, compared to a net loss of USD4.23m, or USD2.93 per basic and diluted loss per share, for the same period a year ago.
As of 31 March 2025 the company had cash and cash equivalents of USD12.78m, an increase from USD2.30m as of 31 March 2024.
Ridgetech reports financial results for fiscal year to March 2026
AMGEN announces Q3 2026 dividend
West Pharmaceutical Services declares quarterly dividend of USD0.22 per share
MedPal AI acquires eMARx to expand digital care home platform
Valerio Therapeutics signs R&D collaboration with Abivax and outlines pipeline milestones
Labcorp declares quarterly dividend of USD0.72 per share
Aptamer Group launches Optimer-based Ebola diagnostic programme
SK bioscience to lead Gates Foundation-funded ROTOR project
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases